Is there any increased risk of hypertension, diabetes and cardiac diseases in psoriatic patients with TNF-? G238A and G308A polymorphism?

Basit Öğe Kaydı
dc.authoridHIZ, Meliha Merve/0000-0003-4303-9717
dc.contributor.authorIsik, Selda
dc.contributor.authorHiz, Meliha Merve
dc.contributor.authorKilic, Sevilay
dc.contributor.authorOgretmen, Zerrin
dc.contributor.authorSılan, Fatma
dc.date.accessioned2025-01-27T20:44:21Z
dc.date.available2025-01-27T20:44:21Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Psoriasis is regarded as a complex autoimmune disease with strong genetic background. Psoriatic patients suffer from many comorbidities including hypertension, diabetes and cardiovascular diseases. Cytokines such as tumor necrosis factor alpha (TNF-alpha) may be a key player that triggers psoriasis and diabetes, hypertension and cardiac disease at the same time. Aim: To evaluate genetic variations in the TNF-alpha region and its association with psoriasis and related comorbidities. Material and methods: The study covered 129 psoriasis patients with three main subgroups with coronary artery disease (n = 41), hypertension (n = 35), and diabetes (n = 21). DNA samples were genotyped for TNF-alpha G308A and G238A polymorphisms by real-time polymerase chain reaction melting-curve analysis and results were compared statistically. Results: Psoriatic patients with both TNF-alpha-298 and TNF-alpha-308 polymorphisms showed no statistically significant increase in the risk of hypertension (OR = 0.425, chi(2) = 1.76, p = 0.18 and OR = 1.87, chi(2) = 1.33, p = 0.25), coronary artery disease (OR = 1.97, chi(2) = 1.91, p = 0.17 and OR = 2.63, chi(2) = 1.35, p = 0.25), or diabetes (OR = 1.35, chi(2) = 0.24, p= 0.62 and OR = 1.53, chi(2) = 0.24, p = 0.62). Conclusions: The current preliminary results suggested that there was no correlation between TNF-alpha promoter polymorphism and diabetes, hypertension and cardiac disease among psoriatic patients in the Turkish population.
dc.identifier.doi10.5114/pdia.2016.58384
dc.identifier.endpage444
dc.identifier.issn1642-395X
dc.identifier.issue6
dc.identifier.pmid28035221
dc.identifier.scopus2-s2.0-85001969682
dc.identifier.scopusqualityQ2
dc.identifier.startpage440
dc.identifier.urihttps://doi.org/10.5114/pdia.2016.58384
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24547
dc.identifier.volume33
dc.identifier.wosWOS:000389786000007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofPostepy Dermatologii I Alergologii
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectpsoriasis
dc.subjectdiabetes
dc.subjecthypertension
dc.subjecttumor necrosis factor alpha
dc.subjectG298A
dc.subjectG308A
dc.titleIs there any increased risk of hypertension, diabetes and cardiac diseases in psoriatic patients with TNF-? G238A and G308A polymorphism?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu